Increased levels of ROS in CKD patients lead to the activation of pro-inflammatory pathways, including the NF-κB pathway, which upregulates the production of pro-inflammatory cytokines such as TNF-α and IL-6 [50]. This evidence concerns the gene IL6 and chronic kidney disease.